Tests a wearable neuromodulation suit in people with stroke or multiple sclerosis
Tests a stimulation suit against a placebo suit in adults with stroke or multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Functional and Quality of Life Effects of the Mollii Neuromodulatory Suit in Patients With Stroke and Multiple Sclerosis
Key facts
- Where
- Kaposvár, HungarySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07333222, who can take part
Where in Hungary
- Somogy County Kaposi Mór Teaching HospitalKaposvár, HungaryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Somogy Megyei Kaposi Mór Teaching Hospital
- Trial code
- NCT07333222
- Record updated
- 12 January 2026
- Original description
* Objective assessment of clinical symptoms resulting from stroke, as well as changes in mobility and quality of life, and determination of changes resulting from therapies * Objective assessment of the quality of life, functionality, and clinical symptoms of patients with multiple sclerosis (MS) and determination of changes resulting from therapies * Comparison of measured data from the two main neurological patient groups (stroke, multiple sclerosis) and follow-up of changes in relation to themselves and each other. * Mapping the role of the placebo effect in neuromodulation devices by comparing subjective and objective outcomes. * Analyzing the expectations and experiences of patients receiving placebo treatment using quality of life questionnaires. * Analyzing the effects of the Mollii suit among subgroups of MS and stroke patients. * Assessing the safety, possible side effects, and tolerability of the Mollii suit. * Mapping changes in gait pattern due to the effects of therapy using 3D motion analysis. * Examining the maintenance effects of neuromodulation during a 1-month follow-up.Read full original descriptionShow less
Prospective, Placebo-controlled Study on the Functional and Quality of Life Effects of the Mollii Neuromodulatory Suit in Patients With Stroke and Multiple Sclerosis
* Objective assessment of clinical symptoms resulting from stroke, as well as changes in mobility and quality of life, and determination of changes resulting from therapies * Objective assessment of the quality of life, functionality, and clinical symptoms of patients with multiple sclerosis (MS) and determination of changes resulting from therapies * Comparison of measured data from the two main neurological patient groups (stroke, multiple sclerosis) and follow-up of changes in relation to themselves and each other. * Mapping the role of the placebo effect in neuromodulation devices by comparing subjective and objective outcomes. * Analyzing the expectations and experiences of patients receiving placebo treatment using quality of life questionnaires. * Analyzing the effects of the Mollii suit among subgroups of MS and stroke patients. * Assessing the safety, possible side effects, and tolerability of the Mollii suit. * Mapping changes in gait pattern due to the effects of therapy using 3D motion analysis. * Examining the maintenance effects of neuromodulation during a 1-month follow-up.
Inclusion: suffered a first ischemic stroke, diagnosed by a neurologist based on CT or MR imaging; neurological examination revealed mobility and postural limitations; confirmed multiple sclerosis diagnosed by a neurologist based on MRI imaging.
Exclusion: irregular medication use; drug use; current participation in individual or group exercise program outside of standard physical therapy; severe heart disease; seizure disorder; untreated diabetes; severe visual or hearing impairment; other neurological conditions affecting motor function; smoking after diagnosis of stroke; multiple strokes in medical history; systolic blood pressure less than 120 or higher than 160 mmHg; orthostatic hypotension; arotid artery stenosis; hemophilia; traumatic brain injury; abnormal electroencephalography; abnormal blood panel; use of sedatives; severe aphasia (Western Aphasia Battery ≤ 25); severe sensory dysfunction; severe orthopedic problems; alcoholism; unable to walk at least 10 m with or without assistance in 6 minutes; BBS score ≤ 32; BI score ≤ 70.